

Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS EXPRESS	JUNE 27 08		CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:52:26 ON 03 MAR 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 08:52:38 ON 03 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2009 HIGHEST RN 1114066-48-6

DICTIONARY FILE UPDATES: 1 MAR 2009 HIGHEST RN 1114066-48-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10588235 str 1.str

L1 STRUCTURE UPLOADED

=> s l1 sss full

FULL SEARCH INITIATED 08:53:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 209 TO ITERATE

100.0% PROCESSED 209 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L2 2 SEA SSS FUL L1

=> d 12

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN

RN 862855-49-0 REGISTRY

ED Entered STN: 09 Sep 2005

CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[2-

methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-  
β-methyl-, (βR)- (CA INDEX NAME)


FS STEREOSEARCH

MF C30 H30 N4 O5

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

188.41

188.63

FILE 'CAPLUS' ENTERED AT 08:53:37 ON 03 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Mar 2009 VOL 150 ISS 10

FILE LAST UPDATED: 2 Mar 2009 (20090302/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12

L3 2 L2

=> d 13 1-2 ibib ab

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:281174 CAPLUS

DOCUMENT NUMBER: 146:330828

TITLE: Pharmaceutical compositions containing  $\alpha$ -4 integrin mediated cell adhesion inhibitors

INVENTOR(S): Ward, Robert William; Witherington, Jason

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 38pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007063268	A	20070315	JP 2006-212923	20060804
PRIORITY APPLN. INFO.:			JP 2005-227980	A 20050805

OTHER SOURCE(S): MARPAT 146:330828

AB The invention relates to a pharmaceutical composition characterized by containing a

compound I [A, B, D = aryl, heteroaryl; R1, R2, R3 = C1-6 alkyl, halogen, C1-6 alkoxy, hydroxy, cyano, CF3, OCF3, nitro, C1-6 alkylthio, amino, mono-(di-)-C1-6 alkylamino, carboxy, C1-6 alkanoyl, amido, mono-(di-)-C1-6 alkylamido, etc; R4, R4' = H, C1-6 alkyl, halogen, C1-6 alkoxy; V = O, S, NH, N-C1-6 alkyl, NNO2, NCN; W, X, Y, Z = C, CH, N, wherein at least one of X, Y, and Z is N; L = -(CH2)q-, -(CH2)q'O-, wherein q = 0-3, q' = 2, 3; J = -CR5:CR6-, wherein R5, R6 = H, C1-6 alkyl, single bond, etc.; m, n, p = 0-3; t = 0-2], or its pharmaceutically acceptable derivative as an active component. The compound has an inhibitory effect against  $\alpha$ -4 integrin mediated cell adhesion, and is suitable for use for treatment of  $\alpha$ -4 integrin mediated cell adhesion-related disease, e.g. asthma, enteritis, rheumatic arthritis, and multiple sclerosis, etc. For example, a compound (R,S)-3-[4-[5-[3-ethoxy-4-(3-o-tolylureido)phenyl]-6-oxo-6H-pyrimidin-1-ylmethyl]phenyl]butyric acid was prepared, and examined for its interaction with integrin VLA-4 in vitro.

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:823674 CAPLUS

DOCUMENT NUMBER: 143:229873

TITLE: Preparation of 2-(phenylmethyl)pyrimidinones and related compounds as  $\alpha$ -4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases

INVENTOR(S): Ward, Robert William; Witherington, Jason

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075438	A1	20050818	WO 2005-JP2194	20050208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2554705	A1	20050818	CA 2005-2554705	20050208
EP 1737826	A1	20070103	EP 2005-710195	20050208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1918133	A	20070221	CN 2005-80004473	20050208
JP 2007522146	T	20070809	JP 2006-552027	20050208
US 20080234301	A1	20080925	US 2006-588235	20060803
PRIORITY APPLN. INFO.:			GB 2004-2812	A 20040209
			WO 2005-JP2194	W 20050208

OTHER SOURCE(S): CASREACT 143:229873; MARPAT 143:229873

AB Title compds. I [R1' = (R1)m; R2' = (R2)n; D = (CH2)t; R3' = (R3)p; R1, R2, R3 = alkyl, halo, alkoxy, etc.; R4, R4' = H, alkyl, halo, etc.; V = O, S, NH, etc.; W, X, Y, Z = C, CH, N, subject to the proviso that at least one X Y and Z is N; L = (CH2)q, (CH2)q'O; J = bond, CR5=CR6, CHR7CHR8, etc.; R5, R6 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, etc.; q = 0-3; q' = 2,3; A, B, D = aryl, heteroaryl; m, n, p = 0-3; t = 0-2] and their pharmaceutically acceptable salts were prepared For example, saponification of Et ester II (G = OEt) afforded carboxylic acid II (G = OH). Compounds I are claimed to be useful as alpha-4 integrin mediated cell adhesion inhibitors (no data provided).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 1-2 ibib ab hitstr

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:281174 CAPLUS

DOCUMENT NUMBER: 146:330828

TITLE: Pharmaceutical compositions containing  $\alpha$ -4 integrin mediated cell adhesion inhibitors

INVENTOR(S): Ward, Robert William; Witherington, Jason

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 38pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007063268	A	20070315	JP 2006-212923	20060804
PRIORITY APPLN. INFO.:			JP 2005-227980	A 20050805
OTHER SOURCE(S): MARPAT 146:330828				

AB The invention relates to a pharmaceutical composition characterized by containing a

compound I [A, B, D = aryl, heteroaryl; R1, R2, R3 = C1-6 alkyl, halogen, C1-6 alkoxy, hydroxy, cyano, CF3, OCF3, nitro, C1-6 alkylthio, amino, mono-(di-)-C1-6 alkylamino, carboxy, C1-6 alkanoyl, amido, mono-(di-)-C1-6 alkylamido, etc; R4, R4' = H, C1-6 alkyl, halogen, C1-6 alkoxy; V = O, S, NH, N-C1-6 alkyl, NNO2, NCN; W, X, Y, Z = C, CH, N, wherein at least one of X, Y, and Z is N; L = -(CH2)q-, -(CH2)q'O-, wherein q = 0-3, q' = 2, 3; J = -CR5:CR6-, wherein R5, R6 = H, C1-6 alkyl, single bond, etc.; m, n, p = 0-3; t = 0-2], or its pharmaceutically acceptable derivative as an active component. The compound has an inhibitory effect against  $\alpha$ -4 integrin mediated cell adhesion, and is suitable for use for treatment of  $\alpha$ -4 integrin mediated cell adhesion-related disease, e.g. asthma, enteritis, rheumatic arthritis, and multiple sclerosis, etc. For example, a compound (R,S)-3-[4-[5-[3-ethoxy-4-(3-o-tolylureido)phenyl]-6-oxo-6H-pyrimidin-1-ylmethyl]phenyl]butyric acid was prepared, and examined for its interaction with integrin VLA-4 in vitro.

IT 862855-36-5P 862855-49-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pharmaceutical compns. containing  $\alpha$ -4 integrin mediated cell adhesion inhibitors)

RN 862855-36-5 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-49-0 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]- $\beta$ -methyl-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:823674 CAPLUS

DOCUMENT NUMBER: 143:229873

TITLE: Preparation of 2-(phenylmethyl)pyrimidinones and related compounds as alpha-4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases

INVENTOR(S): Ward, Robert William; Witherington, Jason

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075438	A1	20050818	WO 2005-JP2194	20050208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2554705	A1	20050818	CA 2005-2554705	20050208
EP 1737826	A1	20070103	EP 2005-710195	20050208
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1918133	A	20070221	CN 2005-80004473	20050208
JP 2007522146	T	20070809	JP 2006-552027	20050208
US 20080234301	A1	20080925	US 2006-588235	20060803
PRIORITY APPLN. INFO.:			GB 2004-2812	A 20040209
			WO 2005-JP2194	W 20050208

OTHER SOURCE(S): CASREACT 143:229873; MARPAT 143:229873

AB Title compds. I [R1' = (R1)m; R2' = (R2)n; D = (CH2)t; R3' = (R3)p; R1, R2, R3 = alkyl, halo, alkoxy, etc.; R4, R4' = H, alkyl, halo, etc.; V = O, S, NH, etc.; W, X, Y, Z = C, CH, N, subject to the proviso that at least one X Y and Z is N; L = (CH2)q, (CH2)q'0; J = bond, CR5=CR6, CHR7CHR8, etc.; R5, R6 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, etc.; q = 0-3; q' = 2,3; A, B, D = aryl, heteroaryl; m, n, p = 0-3; t = 0-2] and their pharmaceutically acceptable salts were prepared For example, saponification of Et

ester II (G = OEt) afforded carboxylic acid II (G = OH). Compounds I are claimed to be useful as alpha-4 integrin mediated cell adhesion inhibitors (no data provided).

IT 862855-36-5P 862855-49-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-(phenylmethyl)pyrimidinones and related compds. as alpha-4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases)

RN 862855-36-5 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -methyl-4-[[3-[4-[[[(2-

methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1 (2H)-pyrazinyl]methyl]-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-49-0 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-methoxy-4-[[[2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1 (2H)-pyrazinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT